Massimo Calafiore Sells 9,797 Shares of Orthofix Medical (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,797 shares of Orthofix Medical stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.21, for a total value of $149,012.37. Following the completion of the transaction, the chief executive officer directly owned 217,237 shares in the company, valued at approximately $3,304,174.77. This represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 9th, Massimo Calafiore sold 9,600 shares of Orthofix Medical stock. The shares were sold at an average price of $15.82, for a total value of $151,872.00.

Orthofix Medical Trading Down 3.3%

Shares of Orthofix Medical stock opened at $14.32 on Thursday. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $20.48. The company’s fifty day simple moving average is $15.38 and its 200-day simple moving average is $14.26. The company has a market cap of $567.07 million, a price-to-earnings ratio of -4.73 and a beta of 0.79. The company has a current ratio of 2.47, a quick ratio of 1.38 and a debt-to-equity ratio of 0.39.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Stifel Nicolaus began coverage on Orthofix Medical in a report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Barrington Research lifted their price objective on Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CWM LLC boosted its holdings in Orthofix Medical by 99.0% during the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after purchasing an additional 955 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in Orthofix Medical in the 3rd quarter valued at $30,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Orthofix Medical in the 2nd quarter valued at $147,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Orthofix Medical by 32.6% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 13,297 shares of the medical device company’s stock valued at $148,000 after acquiring an additional 3,271 shares during the period. Finally, Mackenzie Financial Corp acquired a new position in Orthofix Medical during the third quarter worth $148,000. Institutional investors own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.